XML 172 R115.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Impairment of intangible assets and property, plant and equipment - Summary of Net Impairment Losses of Other Intangible Assets (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of intangible assets |  | € 248 | € 896 | [1] | € (429) | [1]
Eloctate [Member] |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Reversal amount |  |  |  |  | 2,154 |
Biopharma (operating segment) |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 415 |  |  |  |
ALTUVIIIO |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Reversal amount |  |  |  |  | 2,800 |
Other intangible assets |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 265 | 932 |  | (454) |
Other intangible assets | Biopharma (operating segment) |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 225 |  |  |  |
Other intangible assets | Marketed products |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | (167) | 0 |  | (1,561) |
Other intangible assets | Research and development projects and technology platforms |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) | [2],[3],[4] | 415 | 896 |  | 1,107 |
Other intangible assets | Others |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 17 | 36 |  | 0 |
Research and development projects and technology platforms | Eloctate [Member] |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  | 600 |
Reversal amount |  |  |  |  | 600 |
Research and development projects and technology platforms | SAR444245 |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  | 1,586 |
Research and development projects and technology platforms | NK Cell and ProXTen technology platforms |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  | 833 |  |  |
Research and development projects and technology platforms | Biopharma (operating segment) |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 640 |  |  |  |
Marketed products | Eloctate [Member] |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  | 1,554 |
Marketed products | Enjaymo |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Reversal amount |  | 167 |  |  |  |
Clinical Study | Biopharma (operating segment) |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | 239 |  |  |  |
Biopharma (operating segment) | Other intangible assets | Marketed products |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) | [5] | (167) | 0 |  | (1,526) |
Opella (discontinued operation, see Note D.1.) | Other intangible assets | Marketed products |  |  |  |  |  |
Disclosure of impairment loss and reversal of impairment loss [line items] |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  | € 0 | € 0 |  | € (35) |
[1] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] | (c)For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms.
[3] | (b)For 2024, the monitoring of impairment indicators for other intangible assets led to the recognition of net impairment losses of €415 million, comprising (i) impairment losses of €640 million against various research and development projects - including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - and (ii) an impairment reversal of €225 million recognized in connection with the disposal of the ProXTen technology platform.
[4] | (d)For 2022, this amount mainly comprises: –an impairment loss of €1,586 million taken against the development project for SAR444245 (non-alpha interleukin-2), recognized following revised cash flow projections reflecting unfavorable developments in the launch schedule; –the €600 million reversal relating to the BIVV001 project (see above). As required by IFRS 5, the other intangible assets of Opella were measured in accordance with IAS 36 immediately before their reclassification as assets held for sale; this assessment did not result in any impairment of their carrying amount being recognized.
[5] | (a) For 2024, this comprises a reversal of €167 million in connection with the disposal of Enjaymo. For 2022, this amount mainly comprises a reversal of €2,154 million of impairment losses taken against Eloctate and BIVV001 (assets belonging to the Eloctate franchise), consisting of €1,554 million for marketed products and €600 million for research and development projects respectively. In 2019, the launch of competing products for Eloctate led Sanofi to update its sales forecasts for products belonging to the franchise, as a result of which impairment losses of €2.8 billion were recognized against the assets in question. The reversal reflects the approval by the FDA on February 22, 2023 of ALTUVIIIO (the commercial name of efanesoctocog alpha, corresponding to the BIVV001 project), which was submitted in 2022.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfImpairmentLossAndReversalOfImpairmentLossLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2023-01-01 -Paragraph 118 -Subparagraph e -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Impairment loss on intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount + References No definition available. + Details
Name: | sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_ALTUVIIIOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_MarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_OtherProductAndServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_SAR444245Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_NKCellAndProXTenTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_MarketedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_EnjaymoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ClinicalStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=sny_ConsumerHealthcareSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |